Quick filters
- Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies from Multiple Presentations at ASH Annual Meeting Business Wire | Sunday December 9, 2012 9:00AM
- Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides Business Wire | Monday November 26, 2012 9:00AM
- Seattle Genetics to Present at Credit Suisse Healthcare Conference Business Wire | Friday November 9, 2012 9:00AM
- Seattle Genetics Reports Third Quarter 2012 Financial Results Business Wire | Wednesday November 7, 2012 4:05PM
- Seattle Genetics' ASH 2012 Presentations Highlight ADCETRIS® and Demonstrate Leadership in the Development of Antibody-Drug Conjugates (ADCs) Business Wire | Monday November 5, 2012 2:11PM
- Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma Business Wire | Thursday November 1, 2012 8:00AM
- Seattle Genetics Announces ADCETRIS® Receives European Commission Conditional Marketing Authorization Business Wire | Wednesday October 31, 2012 7:00AM
- Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2012 Financial Results on November 7, 2012 Business Wire | Wednesday October 24, 2012 9:00AM
- Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Abbott Business Wire | Tuesday October 23, 2012 9:00AM
- Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS® as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and Over Business Wire | Wednesday October 17, 2012 9:00AM
- Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development Business Wire | Tuesday October 9, 2012 9:00AM
- The biggest R&D spenders: Where innovation pays off Globe and Mail | Tuesday October 2, 2012 8:11PM
- Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant Patients with Hodgkin Lymphoma Business Wire | Tuesday September 25, 2012 9:00AM
- Seattle Genetics to Present at Upcoming Investor Conferences Business Wire | Wednesday September 5, 2012 9:00AM
- Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell Carcinoma Business Wire | Friday August 24, 2012 9:00AM
- Seattle Genetics Reports Second Quarter 2012 Financial Results Business Wire | Wednesday August 8, 2012 4:05PM
- Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2012 Financial Results on August 8, 2012 Business Wire | Thursday July 26, 2012 9:00AM
- Seattle Genetics Announces ADCETRIS® Receives Positive CHMP Opinion for Conditional Approval in European Union Business Wire | Friday July 20, 2012 10:45AM
- Seattle Genetics Highlights Updated Survival Data from ADCETRIS® Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma Business Wire | Thursday June 14, 2012 7:00AM
- Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer Business Wire | Monday June 4, 2012 9:00AM
Live Discussion of SGEN on StockTwits